News

The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.

The next important area of therapeutic development in MS appears to be in disease damage repair.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

The monoclonal antibody has shown continued success up to 8 years in clinical trials.

One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.

A novel mesenchymal stem cell therapy produced intriguing phase II data and has moved into a randomized, pivotal phase III clinical trial.

Dengue infection predominantly causes arthritis, fever, headache, and rash; hemorrhagic and neurologic manifestations may also result. What was the prognosis for this patient?

Physicians offer perspectives on newly approved products to prevent migraine.

Learn about the most insightful article Dr Lazzara has ever read in a research journal.

Neurology News Network for the week of Oct. 12, 2018.

Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.

IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.

Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.

What differentiates migraine from underlying intracranial pathology that may require neuroimaging, like tumors, abscesses, aneurysms, or hemorrhages? Test your skills with this 5-question quiz.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

Over 10 million Americans suffer from debilitating chronic pain, according to new data that provides insights into the unrelenting problem of pain in America.

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.